There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Amedisys (AMED – Research Report), CSL (CMXHF – Research Report) and Outset Medical (OM – Research Report) with bullish sentiments.
Amedisys (AMED)
RBC Capital analyst Ben Hendrix maintained a Buy rating on Amedisys on January 24 and set a price target of $114.00. The company’s shares closed last Wednesday at $92.08, close to its 52-week low of $79.30.
According to TipRanks.com, Hendrix is a 2-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Amedisys with a $113.38 average price target, implying a 25.0% upside from current levels. In a report issued on January 17, Jefferies also maintained a Buy rating on the stock with a $120.00 price target.
See today’s best-performing stocks on TipRanks >>
CSL (CMXHF)
RBC Capital analyst Craig Wong-Pan maintained a Buy rating on CSL on January 23 and set a price target of A$347.00. The company’s shares closed last Wednesday at $207.50, close to its 52-week high of $210.25.
According to TipRanks.com, Wong-Pan is a 3-star analyst with an average return of
Currently, the analyst consensus on CSL is a Strong Buy with an average price target of $233.52, a 12.5% upside from current levels. In a report issued on January 18, Citigroup also maintained a Buy rating on the stock with a A$335.00 price target.
Outset Medical (OM)
RBC Capital analyst Shagun Singh Chadha maintained a Buy rating on Outset Medical on January 23 and set a price target of $31.00. The company’s shares closed last Wednesday at $28.37.
According to TipRanks.com, Chadha is a 2-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Outset Medical with a $30.00 average price target, representing a 9.0% upside. In a report issued on January 12, Stifel Nicolaus also maintained a Buy rating on the stock with a $31.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on AMED:
- Amedisys price target lowered to $115 from $140 at Credit Suisse
- Amedisys to Present at the 41st Annual J.P. Morgan Healthcare Conference
- Computerworld Names Amedisys to 2023 List of Best Places to Work in IT
- Amedisys closes on home health JV with University of Arkansas
- Amedisys Completes Home Health Joint Venture with the University of Arkansas for Medical Sciences
